Knight Therapeutics (FRA:04K) Common Stock: €331.3 Mil (As of Mar. 2026)


FRA:04K Knight Therapeutics Inc FRA:04K
73 GF Score
Price €6.20
GF Value €5.47
! 6 Warning Signs
View Full Analysis

What is Knight Therapeutics Common Stock?

Knight Therapeutics FRA:04K +0.81% 73 Common Stock is €331.3 Mil as of Mar. 2026. GuruFocus rates FRA:04K with a GF Score™ of 73/100 and a GF Value™ of €5.47. The stock has 6 warning signs investors should review.

Knight Therapeutics's quarterly common stock increased from Sep. 2025 (€328.1 Mil) to Dec. 2025 (€328.2 Mil) and increased from Dec. 2025 (€328.2 Mil) to Mar. 2026 (€331.3 Mil).

Knight Therapeutics's annual common stock declined from Dec. 2023 (€369.1 Mil) to Dec. 2024 (€358.1 Mil) and declined from Dec. 2024 (€358.1 Mil) to Dec. 2025 (€328.2 Mil).

Knight Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Knight Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics Common Stock Chart

Knight Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 434.79 416.27 369.13 358.13 328.19

Knight Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 342.24 337.87 328.13 328.19 331.33
FRA:04K
73GF Score
Knight Therapeutics Inc FRA:04K
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Knight Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €331.3 Mil mean?
Knight Therapeutics (FRA:04K) has a Common Stock of €331.3 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Knight Therapeutics and its competitors.
Is Knight Therapeutics' Common Stock too high?
Knight Therapeutics' current Common Stock is €331.3 Mil. Overall, Knight Therapeutics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Common Stock compare to ZTS and UTHR?
Knight Therapeutics' Common Stock of €331.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Knight Therapeutics and its competitors. Knight Therapeutics's current Common Stock is €331.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Knight Therapeutics (FRA:04K) has a current Common Stock of €331.3 Mil. The stock's GF Value™ is €5.47, compared to a current price of €6.20 — trading 13.3% above its estimated fair value. The current Common Stock is €331.3 Mil. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Knight Therapeutics (FRA:04K), the current Common Stock is €331.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (FRA:04K) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of €6.20 is trading 13.3% above its estimated GF Value™ of €5.47.

Key valuation signals for FRA:04K:

  • Common Stock: €331.3 Mil
  • GF Value™: €5.47 vs. price of €6.20 (13.3% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the FRA:04K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Knight Therapeutics Business Description

Other Exchanges KHTRF:USAGUD:Canada
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score

Get the complete analysis for FRA:04K

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.20
Price
€5.47
GF Value